Strategic Advisory Committee
Carsten Laue, PhD
Carsten Laue heads the management team in his role as Chief Executive Officer. Formerly the Chief Executive of a Swiss Contract Research Organization and a researcher at IMD Business School in Lausanne, Switzerland, he brings extensive experience in CE-marking of medical devices, and clinical development.
Dr. Laue holds a PhD from the Swiss Federal Institute of Technology in Lausanne.
Ted P. Werblin, MD, PhD
Inventor and co-founder - Chief Medical Officer
Ted Werblin is a practicing ophthalmic surgeon and associate clinical professor of ophthalmology at the University of Virginia in Charlottesville, USA. Dr Werblin is the inventor of IVO’s intraocular lens technology. He serves as Chief Medical Officer.
He is the author of numerous scientific publications in journals including the Journal of Cataract & Refractive Surgery and the Journal of Refractive Surgery and performs around 500 surgical cases per year.
Dr. Werblin earned his MD and PhD from New York University. He completed his residency in Ophthalmology at Johns Hopkins University, the Wilmer Institute in Baltimore MD. followed by a two year fellowship with Herb Kaufman in Cornea and External Disease at Louisiana State University in New Orleans, LA. He certified by the American Board of Ophthalmology, the National Board of Medical Examiners, and the American Board of Internal Medicine.
Dr. Werblin reviews for the major cataract peer review journals.
Director of Investments at Alsace Capital
Jean-François Rax is a graduate from INSA (Lyon), joined Alsace Capital in April 2014 as Investment Manager of the seed fund Cap Innov’Est.
Prior to joining Alsace Capital and since 2008, Jean-François was an Analyst at Inserm Transfert Initiative, French seed fund dedicated to life sciences and human health. Owing to his previous experiences, he has also a solid background in company creation, technology transfer, licensing and marketing strategy.
Eric Desjardins served for 14 years as vice president of international sales for Aaren Scientific Inc. Ontario in California, where he was responsible of 95% of Aaren Scientific sales. He participated in the main surgical conferences around the world and also oversaw clinical trials of new products. The company was sold to Zeiss 3.5 times sales in 2014 to $ 70 million. Before that he was CEO of Coherent SA Orsay 91, the medical unit of Coherent Inc. San Jose CA USA. During his long career in the ophthalmic field, he worked for Corneal Laboratories, Paris, IOPTEX Inc. USA, Hexavision SA, Paris and Coopervision SA, Paris.
Jean-Marc Le Doussal
President of Remora Capital SA